Pro Pharmaceuticals Group has launched a new initiative to support hospitals with early visibility on emerging medicine supply pressures. This service strengthens planning, improves continuity, and helps clinical teams stay ahead of potential disruptions.

Dear Healthcare Professional, Pro Pharmaceuticals Group wishes to advise that the Australian registered product TENOFOVIR DISOPROXIL/EMTRICITABINE/EFAVIRENZ Viatris 300/200/600  (AUST R: 280721) is currently in shortage, as listed on the TGA Medicines Shortage Database. To ensure continuity of care, the TGA has granted approval under Section 19A of the Therapeutic Goods Act 1989 for supply of an alternative product: Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate T